News
VIR
7.63
-5.10%
-0.41
Weekly Report: what happened at VIR last week (0415-0419)?
Weekly Report · 4d ago
Vir Biotechnology Announces CFO Departure and Board Expansion
TipRanks · 04/18 13:02
On April 15, 2024, Sung Lee, Executive Vice President And Chief Financial Officer Of Vir Biotechnology Informed The Company That He Will Be Stepping Down From His Role, Effective May 3, 2024, To Pursue Another Career Opportunity; Co Has Initiated A Search For His Successor
Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc., will step down from his role effective May 3, 2024. Mr. Lee's resignation was not because of any disagreement with the Company. The Company has initiated a search for his successor.
Benzinga · 04/18 12:49
VIR BIOTECHNOLOGY ANNOUNCES NOMINATION OF NORBERT BISCHOFBERGER, PH.D. AND RAMY FARID, PH.D. TO ITS BOARD OF DIRECTORS
Reuters · 04/18 12:00
Weekly Report: what happened at VIR last week (0408-0412)?
Weekly Report · 04/15 09:13
VIR BIOTECHNOLOGY TO PROVIDE BUSINESS UPDATE AND REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 2, 2024
Reuters · 04/11 20:30
Weekly Report: what happened at VIR last week (0401-0405)?
Weekly Report · 04/08 09:13
Have Vir Biotechnology Insiders Been Selling Stock?
Vir Biotechnology, Inc. CEO & Director Marianne De Backer sold US$690k worth of stock at a price of US$9.46 per share. The biggest insider sale of Vir Biotechnology shares in the last year is by the CEO. Insiders own 5.3% of the company, but the company didn't buy any shares over the last 12 months. It's important to note that the sale of shares was at a lower price than the current share price. You can see the insider transactions at Vir Biotech in the United States.
Simply Wall St · 04/06 12:32
Weekly Report: what happened at VIR last week (0325-0329)?
Weekly Report · 04/01 09:13
Weekly Report: what happened at VIR last week (0318-0322)?
Weekly Report · 03/25 09:13
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street
Congress is considering a bill to blacklist certain Chinese biotech companies. U.S. Companies have outsourced contract manufacturing and research to Chinese companies. The bill could have unintended consequences for companies that rely on those companies for drug development. Congress is considering the legislation to protect national-security concerns.
The Wall Street Journal · 03/23 13:00
Weekly Report: what happened at VIR last week (0311-0315)?
Weekly Report · 03/18 09:13
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Vir Biotechnology (NASDAQ:VIR) has been analyzed by 5 analysts in the last three months. Vir Biotechnology has an average 12-month price target of $64.8. The company is an immunology company focused on treating and preventing serious infectious diseases. The average price target has increased by 22.26% from the previous average.
Benzinga · 03/15 14:00
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)
TipRanks · 03/15 10:20
Weekly Report: what happened at VIR last week (0304-0308)?
Weekly Report · 03/11 09:13
Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning
TipRanks · 03/11 04:46
Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial
Benzinga · 03/05 13:06
Weekly Report: what happened at VIR last week (0226-0301)?
Weekly Report · 03/04 09:13
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Vir Biotechnology is developing treatments for Hepatitis B, Hep atitis Delta, HIV, and COVID. Initial data from the SOLSTICE trial in patients with hepatitis delta virus showed promising results. The company is expected to report additional data from its HB and HD trials in Q2'24.
Seeking Alpha · 02/28 04:56
Vir Biotechnology, Inc.: Statement of changes in beneficial ownership of securities
Press release · 02/27 10:04
More
Webull provides a variety of real-time VIR stock news. You can receive the latest news about Vir Biotechnology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VIR
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.